TransmedicsTMDX
About: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Employees: 728
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
31% more repeat investments, than reductions
Existing positions increased: 118 | Existing positions reduced: 90
30% more call options, than puts
Call options by funds: $70.5M | Put options by funds: $54.1M
14% more capital invested
Capital invested by funds: $2.3B [Q4 2024] → $2.62B (+$327M) [Q1 2025]
6.05% more ownership
Funds ownership: 109.76% [Q4 2024] → 115.82% (+6.05%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
4% less funds holding
Funds holding: 309 [Q4 2024] → 296 (-13) [Q1 2025]
15% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 62
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Piper Sandler Matt O'Brien | 1%upside $145 | Overweight Reiterated | 4 Jun 2025 |
Oppenheimer Suraj Kalia | 9%downside $130 | Outperform Maintained | 9 May 2025 |
Financial journalist opinion
Based on 21 articles about TMDX published over the past 30 days
